Blog
RSS FeedPosted by Michael Wonder on 06 Jul 2020
European Commission grants conditional marketing authorization for Gilead’s Veklury (remdesivir) for the treatment of COVID-19
3 July 2020 - Veklury is the first approved treatment option for COVID-19 in the European Union. ...
Posted by Michael Wonder on 05 Jul 2020
FDA Commissioner says he can't predict when vaccine will be ready after Trump's timeline claims
5 July 2020 - Food and Drug Administration Commissioner Stephen Hahn said Sunday that he would not make a prediction ...
Posted by Michael Wonder on 05 Jul 2020
Switzerland fast-tracks anti-viral medication against COVID-19
2 July 2020 - Swissmedic, the agency that oversees the use of medicaments in Switzerland, took days to fast-track approval ...
Posted by Michael Wonder on 05 Jul 2020
Oxford University is leading in the vaccine race
2 July 2020 - Governments are pouring money into a more urgent version of the space race. ...
Posted by Michael Wonder on 05 Jul 2020
European Commission approves extended Invokana (canagliflozin) indication to reflect improved renal outcomes in patients with diabetic kidney disease and type 2 diabetes seen in CREDENCE study
1 July 2020 - The European Commission approval is based on the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy ...
Posted by Michael Wonder on 03 Jul 2020
FDA approves new HIV treatment for patients with limited treatment options
2 Jul 2020 - Today, the U.S. FDA approved Rukobia (fostemsavir), a new type of anti-retroviral medication for adults living with ...
Posted by Michael Wonder on 03 Jul 2020
MetVital announces FDA fast track designation of anhydrous enol-oxaloacetate for the treatment of patients with newly diagnosed glioblastoma multiforme
1 July 2020 - MetVital today announces that the U.S. FDA has notified MetVital that its lead drug candidate, "Anhydrous ...
Posted by Michael Wonder on 02 Jul 2020
Regression discontinuity design
2 July 2020 - The method is used to study the outcomes related to an abrupt change when it is not ...
Posted by Michael Wonder on 02 Jul 2020
Cochlear calls for low risk health apps to be exempt from TGA register
3 July 2020 - Hearing implant giant Cochlear has called for some low risk health apps to be exempt from ...
Posted by Michael Wonder on 02 Jul 2020
Acacia Pharma announces US FDA approval of Byfavo (remimazolam) for injection for the induction and maintenance of procedural sedation
2 July 2020 - Byfavo is a very rapid onset/offset IV benzodiazepine sedative for use during invasive medical procedures lasting 30 ...
Posted by Michael Wonder on 02 Jul 2020
Gilead donates COVID-19 drug remdesivir to Australia’s medical stockpile after US buys up supply
2 July 2020 - The US pharmaceutical giant Gilead has donated a supply of the anti-viral medication remdesivir to Australia’s ...
Posted by Michael Wonder on 02 Jul 2020
European Commission approves Daurisma (glasdegib) for certain adult patients with newly diagnosed acute myeloid leukaemia
30 June 2020 - Pfizer today announced that the European Commission approved Daurisma (glasdegib), a Hedgehog pathway inhibitor, in combination with ...
Posted by Michael Wonder on 02 Jul 2020
Johnson & Johnson announces European Commission approval for Janssen’s preventive Ebola vaccine
1 July 2020 - This marks the first major regulatory approval of a vaccine developed by Janssen. ...
Posted by Michael Wonder on 02 Jul 2020
Rhythm Pharmaceuticals receives rare paediatric disease designation from U.S. FDA for setmelanotide for treatment of POMC and LEPR deficiency obesities
1 July 2020 - Rhythm Pharmaceuticals today announced that the U.S. FDA has granted rare paediatric disease designations for setmelanotide, an ...
Posted by Michael Wonder on 02 Jul 2020
Rhythm Pharmaceuticals announces submission of marketing authorization application to the European Medicines Agency for setmelanotide in POMC and LEPR deficiency obesities
1 July 2020 - Company also announces positive data from eight supplemental patients, including four paediatric patients, enrolled in pivotal ...